Journal of Clinical Oncology
Articles in this Issue
DATO-Base: A phase II study of DATOpotamab deruxtecan for patients with breast cancer brain metastases or leptomeningeal disease.
TPS1134 Background: Approximately half of patients with metastatic TNBC and one fifth of those with estrogen receptor (ER)+/HER2-negative metastatic breas...
AI-driven transcriptomic classification of glioblastoma: Associations with survival and tumor microenvironment.
2042 Background: Glioblastoma (GBM) is the most lethal primary brain tumor in adults, with a median survival of ~15 months despite current therapies (surg...
Bispecific innate cell engager (ICE) AFM24 in combination with atezolizumab in patients with advanced/metastatic <i>EGFR</i> -expressing non-small cell lung cancer (NSCLC) without driver mutations: Initial results from a phase 2a study.
2609 Background: Novel treatments are needed for patients with advanced/metastatic NSCLC without actionable driver mutations who progress after prior ther...
Clinical and prognostic implications of the TCR repertoire in leiomyosarcoma.
11573 Background: Leiomyosarcomas (LMS) are aggressive mesenchymal tumors sometimes classified by primary location as uterine LMS (uLMS) versus extra-uter...
Longitudinal analysis of cancer symptom clusters and inflammatory biomarkers: Insights into quality of life in Brazilian breast cancer patients undergoing chemotherapy.
e24045 Background: Chronic inflammation and cancer share a complex relationship. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR),...
Survival outcomes of patients with stage III melanoma treated with adjuvant immunotherapy, with a focus on immune-related adverse events leading to delays in treatment.
e21570 Background: Immunotherapy (IO), particularly immune checkpoint inhibitors (ICIs), has demonstrated promising results when used as adjuvant therapy...
The germline and somatic landscape of uterine leiomyosarcoma.
e17619 Background: Uterine leiomyosarcoma (LMS) is a rare, aggressive cancer arising from uterine soft tissue. Surgical cytoreduction is the cornerstone o...
Survival outcomes for zanidatamab-hrii compared to chemotherapy in previously treated HER2-positive (IHC3+) biliary tract cancer (BTC): HERIZON-BTC-01 vs a real-world (RW) external control arm (ECA).
4101 Background: Zanidatamab-hrii, a bispecific HER2-directed antibody, received accelerated approval for adults with previously treated, unresectable or...
Cadonilimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (BicureX): A phase II, single-arm clinical trial.
e16239 Background: PD-1 or PD-L1 inhibitors plus chemotherapy as the first-line treatment has been proven to be effective in improving the prognosis of ad...
Ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in patients (pts) with relapsed/refractory multiple myeloma (MM): CARTITUDE-4 survival subgroup analyses.
7539 Background: In CARTITUDE-4, a single cilta-cel infusion significantly improved progression-free survival (PFS; hazard ratio [HR] weighted, 0.29 [95%...
Trends and disparities in thyroid cancer mortality in the United States: A 24-year retrospective analysis.
e18161 Background: Thyroid cancer remains a significant cause of mortality globally, with varying trends across demographic, geographic, and socioeconomic...
Decoding HER2 dynamics: Exploring HER2 expression across a real-world breast cancer cohort.
1026 Background: HER2 expression in breast cancer (BC) has evolved from a binary scoring system to a continuum-based approach, driven by the therapeutic b...
A phase III randomized clinical trial evaluating perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB).
4007 Background: Locally advanced Gallbladder cancers (LAGBC)initially deemed not suitable for R0 resection receive either neoadjuvant chemotherapy (NACT)...
Camrelizumab combined with 2 cycles of chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC): A two-arm, single-center, phase 2 study.
8548 Background: In the treatment of advanced non-small cell lung cancer (NSCLC), the combination of anti-PD1 and chemotherapy has demonstrated an advanta...
Circulating tumor DNA (ctDNA) dynamics during anti-PD-1 based therapy to predict clinical outcomes in advanced stage melanoma: A multicenter retrospective study.
9523 Background: ctDNA has shown promise as a prognostic biomarker for disease relapse in resected tumors. The significance of ctDNA changes in the advanc...
Efficacy of macrophage checkpoint Clever-1 inhibition with bexmarilimab plus azacitidine in myelodysplastic syndrome: Results from the ph1/2 BEXMAB study.
6513 Background: Treatment of higher-risk (HR) myelodysplastic syndrome (MDS) represents an unmet medical need. Hypomethylating (HMA) agents, including az...
Real-world treatment patterns and outcomes among patients with advanced NSCLC treated with amivantamab.
e20646 Background: Among patients with non-small cell lung cancer (NSCLC), ~19-24% harbor epidermal growth factor receptor mutations (EGFRm). Amivantamab...
A phase l and randomized phase ll trial of radium-223 dichloride, peposertib, and avelumab in advanced metastatic castrate-resistant prostate cancer (mCRPC): Phase l results.
5069 Background: Ra-223 improves the overall survival in patients with mCRPC to the bone. We assessed the safety of standard-of-care Ra-223 in combination...
Comparing patient-reported wellness outcomes in head and neck cancer patients treated with proton vs photon therapy.
e23209 Background: Radiation therapy is a cornerstone in the treatment of head and neck cancers (HNC). Proton therapy offers a precise approach, deliverin...
A phase I/II study of abemaciclib, a CDK4/6 inhibitor, in participants with HIV-associated and HIV-negative Kaposi sarcoma.
11505 Background: Kaposi sarcoma (KS), caused by Kaposi sarcoma herpesvirus (KSHV), is a multicentric angioproliferative tumor seen in people with and wit...
Are we still ‘choosing wisely’? Predictors of unnecessary staging imaging in US veteran patients with prostate cancer.
e17147 Background: The American Society of Clinical Oncology’s Choosing Wisely (CW) initiative recommends against staging imaging for early-stage prostate...
Administration of tarlatamab in an outpatient setting utilizing remote patient monitoring: Mayo Clinic experience.
1652 Background: Tarlatamab is a bispecific T-cell engager targeting DLL3 that has shown promise as a therapy in small cell lung cancer. Administering tar...
Trends in mantle cell lymphoma: Updated SEER analysis from 2000 to 2021.
e19081 Background: Mantle Cell Lymphoma (MCL) is a rare subtype of Non-Hodgkin Lymphoma (NHL) that is characterized by cyclin-D1 overexpression. The Surve...
A phase 2 study of first-line (1L) domvanalimab (dom), zimberelimab (zim), and chemotherapy (chemo) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Substudy-01 of the VELOCITY-HNSCC platform trial.
e18011 Background: Pembrolizumab (anti–PD-1 monoclonal antibody [mAb]) ± chemo is a recommended 1L treatment strategy for pts with R/M HNSCC. Despite impr...
Clinical factors affecting clinical investigators’ (CIs) selection of CDK4/6 inhibitors (CDKis) for patients with hormone receptor-positive metastatic breast cancer (HR+ mBC).
e13097 Background: The clinical availability of three CDKis for the treatment of HR+ mBC has provided clinicians with important therapeutic options; howev...